Literature DB >> 29930301

The role of neutrophil extracellular traps in rheumatic diseases.

Falko Apel1, Arturo Zychlinsky2, Elaine F Kenny3.   

Abstract

Rheumatic diseases are a collection of disorders defined by the presence of inflammation and destruction of joints and internal organs. A common feature of these diseases is the presence of autoantibodies targeting molecules commonly expressed in neutrophils. These preformed mediators are released by neutrophils but not by other immune cells such as macrophages. Neutrophils, major players in the host innate immune response, initiate a cell death mechanism termed neutrophil extracellular trap (NET) formation as a way to ensnare pathogens. NETs are also a source of released self-molecules found in rheumatic diseases. Subsequently, research on the role of NETs in the onset, progression and resolution of inflammation in rheumatic diseases has intensified. This Review has two aims. First, it aims to highlight the mechanisms required for the generation of NETs, the research landscape of which is rapidly changing. Second, it aims to discuss the role of neutrophils and NETs in systemic lupus erythematosus, vasculitis (specifically anti-neutrophil cytoplasmic autoantibody-associated vasculitis), rheumatoid arthritis and gout. Our goal is to clarify the field of NET research in rheumatic diseases in the hope of improving the therapeutic approaches utilized for these diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29930301     DOI: 10.1038/s41584-018-0039-z

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  56 in total

1.  Transposon Mutagenesis Screen of Klebsiella pneumoniae Identifies Multiple Genes Important for Resisting Antimicrobial Activities of Neutrophils in Mice.

Authors:  Michelle K Paczosa; Rebecca J Silver; Anne L McCabe; Albert K Tai; Colin H McLeish; David W Lazinski; Joan Mecsas
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

2.  Neutrophil extracellular trap-microparticle complexes trigger neutrophil recruitment via high-mobility group protein 1 (HMGB1)-toll-like receptors(TLR2)/TLR4 signalling.

Authors:  Yongzhi Wang; Feifei Du; Avin Hawez; Matthias Mörgelin; Henrik Thorlacius
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

Review 3.  NETosis in Rheumatic Diseases.

Authors:  Mehul P Jariwala; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2021-01-28       Impact factor: 4.592

Review 4.  Evolving story of autoantibodies in systemic lupus erythematosus.

Authors:  David S Pisetsky
Journal:  J Autoimmun       Date:  2019-12-04       Impact factor: 7.094

Review 5.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

Review 6.  Neutrophils as emerging therapeutic targets.

Authors:  Tamás Németh; Markus Sperandio; Attila Mócsai
Journal:  Nat Rev Drug Discov       Date:  2020-01-22       Impact factor: 84.694

Review 7.  New insights into the role of antinuclear antibodies in systemic lupus erythematosus.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2020-09-03       Impact factor: 20.543

Review 8.  Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.

Authors:  Anton Du Preez van Staden; Winschau F van Zyl; Marla Trindade; Leon M T Dicks; Carine Smith
Journal:  Appl Environ Microbiol       Date:  2021-06-25       Impact factor: 4.792

9.  A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.

Authors:  Julie Goswami; Taleen A MacArthur; Meera Sridharan; Rajiv K Pruthi; Robert D McBane; Thomas E Witzig; Myung S Park
Journal:  Shock       Date:  2021-06-01       Impact factor: 3.533

10.  Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases.

Authors:  Jos W G van Rosmalen; Maarten van der Linden; Renato G S Chirivi; Maximilien Euler; Gonny Schmets; Galina Bogatkevich; Konstantinos Kambas; Jonas Hahn; Quinte Braster; Oliver Soehnlein; Markus H Hoffmann; Helmuth H G van Es; Jos M H Raats
Journal:  Cell Mol Immunol       Date:  2020-03-20       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.